The majority of mutations identified in this work have never been associated with PCa, and some are predicted to be damaging, which offers an auspicious opportunity for research and development of PCa biomarkers, especially in the HSPG2 context. The gene discussed is HSPG2; the disease is posterior cortical atrophy.